-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Zhiyi Biotech's Hong Kong Stock IPO The Securities Regulatory Commission requested additional explanation of the reasons, evolution, legal compliance, etc. of equity intermediaries

Zhitongcaijing·11/20/2026 11:17:10
Listen to the news

The Zhitong Finance App learned that on November 20, the China Securities Regulatory Commission issued a notice requesting supplementary materials for overseas issuance and listing registration (November 16, 2026 to November 20, 2026). As mentioned in the announcement, the Securities Regulatory Commission requested Zhiyi Biotech to further explain the reasons for the formation, evolution, legal compliance, whether there are any disputes or potential disputes, and whether the proxy holder is a subject prohibited by laws and regulations during the shareholding period (including whether it violates the prohibition of competition). According to the Hong Kong Stock Exchange's disclosure on June 18, Guangzhou Zhiyi Biotechnology Co., Ltd. (abbreviation: Zhiyi Biotech) submitted a statement to the main board of the Hong Kong Stock Exchange, with SDIC Securities International and Xingzheng International as co-sponsors.

The Securities Regulatory Commission requested Zhiyi Biotech to further explain the following matters, and ask lawyers to check and issue clear legal opinions:

1. Please explain the reasons for the formation, evolution, legal compliance, whether there are disputes or potential disputes, and whether the proxy holder is a subject prohibited from holding shares under laws and regulations during the equity brokerage period (including whether it violates the prohibition of competition).

2. Please explain the pricing basis for the previous capital increases and share transfers, the fairness of the consideration for some share transfers of 1 yuan, and the relevant transferor's income tax payments relating to the above share transfers, and issue a clear conclusion on whether there is a transfer of benefits.

3. Please explain: (1) the status and background of changes in directors and executives during the reporting period; (2) Please explain whether the basis for determining the actual controller is sufficient based on board nominations and decision records during the reporting period.

4. Please explain the progress of the company's state-owned shareholders in processing the state-owned stock logo.

5. Whether the shares held by shareholders who intend to participate in the “full circulation” have been pledged, frozen, or have other rights defects.

According to the prospectus, Zhiyi Biotech is a clinical-stage biopharmaceutical company focusing on the field of live biopharmaceuticals (LBP), and its business covers gastrointestinal diseases, tumors, complications related to tumor treatment, metabolic diseases, and autoimmune diseases. As of the last practical date, the company has a core product SK08, which is an LBP candidate for treating diarrhoeal irritable bowel syndrome (IBS-D), acute childhood diarrhea (rotavirus diarrhea) caused by rotavirus (rotavirus diarrhea), ulcerative colitis (UC), and treatment of advanced solid tumors in combination with anti-PD1/L1 monoclonal antibodies; a key product, SK10, an inactivated LBP candidate for the prevention and treatment of chemotherapy-associated diarrhea (CID); and four pipeline pre-clinical drug candidates.